
NEWS RELEASE

**iX Biopharma secures India patent
for its WaferiX™ drug delivery technology**

- ✓ **India becomes the latest major market to grant patent for the Group's novel WaferiX™ technology**
- ✓ **Group has successfully secured patents in key markets including China, Australia, United Kingdom as well as several other countries in the European Union**

Singapore, 22 October 2019 – Specialty pharmaceutical company **iX Biopharma Ltd** (SGX:42C) (“iX Biopharma” or, together with its subsidiaries, “the Group”) is pleased to announce that it has been granted a patent in India (Patent no. 319759) for its **WaferiX™** drug delivery technology. The patent will expire on 26 October 2030.

WaferiX™ is a multiple drug carrier platform technology that allows pharmacologically active compounds, such as ketamine and sildenafil, to be administered sublingually (i.e. placed under the tongue) and delivered safely, conveniently and rapidly into the blood stream.

Produced via the Group's proprietary freeze-drying technique, the porous and amorphous WaferiX™ matrix holding the active molecules is designed to collapse quickly within the sublingual space before being transported rapidly across the sublingual membrane into the blood vessels for a rapid onset of action. In addition, the technology has also been proven to increase the bioavailability of drug actives as well as predictability of effect.

With India's grant of patent, iX Biopharma's intellectual property rights for its sublingual wafer technology is now secured in key Asian markets including China, Singapore, South Korea, Malaysia, Indonesia and Japan.

Apart from Asia, iX Biopharma has amassed a portfolio of patents in other countries, namely Australia, New Zealand, Canada, South Africa, United Kingdom and countries in the European Union such as Germany, France, Italy, Spain, Netherlands, Turkey, Switzerland, Sweden, Poland, Belgium, Austria, Norway, Denmark, Ireland, as well as Finland.

Ms Eva Tan, Director, Corporate and Commercial Strategy of iX Biopharma commented, “*Moving forward, the Group will continue to leverage on the vast commercial potential of WaferiX™ to develop novel treatment options in order to satisfy unmet medical needs. Supported by a broad and diversified patent portfolio of major markets countries, we are well-positioned to seek out potential export opportunities for WaferiX™ products by way of off-take agreements and out-licensing, so as to diversify our revenue streams and chart new avenues of growth.*”

- The End -

About iX Biopharma Ltd

iX Biopharma is a specialty pharmaceutical and nutraceutical company listed on the Catalist board of the Stock Exchange of Singapore (SGX-ST), operating a fully integrated business model from drug development to manufacturing and supply, with facilities in Australia. The Group is focused on the development and commercialisation of therapies for diseases of the central nervous system using novel, patent-protected formulations for sublingual delivery.

iX Biopharma's pipeline of products under development includes Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management. iX Biopharma's drugs for the treatment of erectile dysfunction, Wafesil, a sublingual sildenafil wafer, and Silcap, have been registered in Australia.

The Group's nutraceuticals division, Entity Health Limited, recently launched its Entity line of nutraceutical products and is engaged in the development and commercialisation of nutraceutical products that address specific conditions and improve quality of life. In addition to the successful registration of Wafesil and Silcap, Entity's nutraceutical products are also listed on the Australian Register of Therapeutic Goods (ARTG).

Contact for media:

Dr Janakan Krishnarajah

Chief Operating Officer and Chief Medical Officer

T: +65 6235 2270

E: j.krishnarajah@ixbiopharma.com

Eva Tan

Director, Corporate and Commercial Strategy

T: +65 6235 3212

E: eva.tan@ixbiopharma.com

Investor Relations:

Kamal Samuel/James Bywater/Jonathan Wee

T: +65 6438 2990

E: Tech@financialpr.com.sg

This announcement has been reviewed by the Company's sponsor, CIMB Bank Berhad, Singapore Branch ("Sponsor") in accordance with Rule 226(2)(b) of the Catalist Rules. This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr. Yee Chia Hsing, Head, Catalist. The contact particulars are 50 Raffles Place, #09-01 Singapore Land Tower, Singapore 048623, telephone: (65) 6337-5115.
